Ticagrelor and Aspirin for the Prevention of Cardiovascular Events After Coronary Artery Bypass Surgery (CABG).

Trial Profile

Ticagrelor and Aspirin for the Prevention of Cardiovascular Events After Coronary Artery Bypass Surgery (CABG).

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 18 Feb 2016

At a glance

  • Drugs Ticagrelor (Primary) ; Aspirin
  • Indications Cardiovascular disorders; Coronary artery disease; Embolism and thrombosis
  • Focus Therapeutic Use
  • Acronyms TAP-CABG
  • Most Recent Events

    • 18 Feb 2016 Primary endpoint has been met (Graft occlusion on CTA at 3 months) as per the results published in the Heart.
    • 18 Feb 2016 Results published in the Heart
    • 24 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top